149+ Premium Assets Across 11 Strategic Clusters
Organ-on-chip platforms, digital twins, cell therapy, quantum drug discovery, AI-biology fusion, microphysiological systems, organoid medicine, CAR-T immunotherapy, synthetic biology, and international MENA/Asia-Pacific markets. Enterprise infrastructure for the $350B+ human simulation medicine market.